Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.…
Minskad förlust för Xintela
Xintela (STO: XINT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 0.1410 SEK on 20 November 2026, down 48.3% over 52 weeks. Its 52-week range is 0.1300 SEK to 0.3500 SEK: the price is 59.7% below the high and 8.5% above the low.
Its market capitalisation is 121.44M SEK.
Xintela reports revenue up 51.0% year over year.
Its debt exceeds its cash by 21.17M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.